Immunotherapy experiments in gastric surgery: current status and future directions

尹玉平,陶凯雄
DOI: https://doi.org/10.3760/cma.j.cn421213-20210624-01184
2022-01-01
Abstract:Gastric cancer is one of the most common malignant diseases worldwide, which ranks the fourth cancer related mortality. The new cases in our country account for 50% around in the whole world. Although D2 surgery combined with chemoradiotherapy and targeted therapy is considered as the standard therapeutic strategy for advanced gastric cancer, the overall outcome is still un-satisfied, and the novel strategy is eagerly needed. Based on the inspiring results of Checkmate649 and Keynote062, chemotherapy combined with PD-1 inhibitors was recommended as the first line strategy for advanced gastric cancer with the CPS score of PD-1 more than 1 or 5, which provided promising perspective for advanced gastric cancer therapy, but there are still some problems and controversies to be solved. Thus, the rational design of clinical trials and investigation of mechanism of immunotherapy was needed to further promote the prognosis of advanced gastric cancer.
What problem does this paper attempt to address?